Table 3.
Results of immune checkpoint inhibitors and combination therapy
| Nivolumab (n = 214) | Pembrolizumab (n = 104) | Pembrolizumab plus lenvatinib (n = 26) | Atezolizumab plus bevacizumaba (n = 73) | SHR-1210 plus apatinib (n = 18) | Durvalumab plus tremelimumab (n = 40) | |
|---|---|---|---|---|---|---|
| ORR, % | 20 (15–26)b | 17 (11–26)b | 42.3 (23.4–63.1)c | 34c | 38.9c | 25b |
| DCR, % | 64 (58–71) | 62 (52–71) | 100 | 75 | 83.3 | 57.5 (>16 weeks) |
| PFS, months | 4.0 (2.9–5.4) | 4.9 (3.4–7.2) | 9.7 (5.6-NE) | 7.5 (0.4–23.9) | 7.2 (2.6-NE) | NA |
| OS, months | NR (9 M, 74%) | 12.9 (9.7–15.5) | NR | NR | NR | NA |
| DOR, months | 9.9 (8.3-NE) | ≤9 (77%) | NE | NR | NE | NA |
Figures in parentheses indicate 95% CI unless otherwise stated. ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; DOR, duration of response; NR, not reached; NE, not estimable; NA, not available.
a
Independent Review Facility (IRF) assessment.
b
RECIST 1.1.
c
Modified RECIST.